{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Teragawa H"],"pubmed_abstract":["<h4>Purpose</h4>The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial.<h4>Patients and methods</h4>We measured the estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, a"],"journal":["Diabetes, metabolic syndrome and obesity : targets and therapy"],"pagination":["685-694"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8901417"],"repository":["biostudies-literature"],"pubmed_title":["Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial."],"pmcid":["PMC8901417"],"pubmed_authors":["Teragawa H","Morimoto T","Shimabukuro M","Sakuma M","Arasaki O","Nomiyama T","Fujii Y","Node K","Ueda S","Ueda T"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.","description":"<h4>Purpose</h4>The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial.<h4>Patients and methods</h4>We measured the estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, a","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T07:50:52.382Z","creation":"2025-04-04T07:50:52.382Z"},"accession":"S-EPMC8901417","cross_references":{"pubmed":["35264863"],"doi":["10.2147/DMSO.S350518"]}}